Machine Learning Application in COVID-19 Drug Development
Publisher
Springer Singapore
Reference29 articles.
1. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33
2. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010a) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214
3. Cummings J, Morstof T, Zhong K (2014) Alzheimer’s disease drug development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37–44
4. Eliopoulos H, Giranda V, Carr R, Tiehen R, Leahy T, Gordon G (2008) Phase 0 trials: an industry perspective. Clin Cancer Res 14(12):3683–3688
5. Xue H, Li J, Xie H, Wang Y (2018) Review of drug repositioning approaches and resources. Int J Biol Sci 14(10):1232